美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

康休

65.60

0.0000

成交量：- -

成交額：- -

市值：127.60億

市盈率：-1.26

高：65.60

開：65.60

低：65.60

收：65.60

52周最高：90.52

52周最低：33.13

股本：1.95億

流通股本：1.92億

量比：- -

換手率：- -

股息：0.73

股息率：1.11%

每股收益(TTM):-52.2669

每股收益(LYR):-3.5480

淨資產收益率：-77.91%

總資產收益率：-30.69%

市淨率：1.64

市盈率(LYR):-18.49

資料載入中...

總覽公司新聞資訊公告

【券商聚焦】交銀國際：CXO行情持續回暖料板塊估值倍數合理

海納醫藥三度衝擊IPO：現金流吃緊、業績持續下滑，仿製藥CXO的故事不好講了

掘金港股醫藥板塊復甦！恒生生物科技 ETF華泰柏瑞（513930）上市，助力一鍵佈局創新藥+CXO 雙賽道

衝高回落！CXO、互聯網醫療力挺，華寶基金港股通醫療ETF（159137）成功連陽！創新藥分化，520880放量收平

國信證券：CXO與器械板塊機會顯現關注創新藥產業鏈及低估值板塊

智通财经网

2025年醫藥生物新股業績透視：CXO產業景氣好轉，創新藥企「摘U」崎嶇，降本增效極致博弈

萬聯證券：投融資與出海雙輪驅動 CXO迎來景氣度修復與全球化新周期

智通财经网

績優股扛旗，藥明系CXO領銜，醫療ETF、港股通醫療華寶ETF雙雙回血！企穩信號出現？

國金證券：國內製藥供應鏈景氣度上行持續建議把握CXO行業兩大核心主線

腦機接口、AI醫療、CXO全面開花！低位佈局港股通醫療ETF（159137）或正當時

CXO行業深度報告：三重紅利共振，開啓新一輪景氣上升周期

國信證券：小核酸CXO行業景氣度持續攀升邁入臨床兑現與商業化加速階段

陳果：春季行情未完，結構如何變化？

國聯民生證券：全球CXO行業強勢復甦 2026年有望延續高景氣

近五成生物醫藥公司業績預喜多家CXO企業表現亮眼

南方财经网

西南證券：CXO行業關注新分子的成長性與國內景氣度修復的傳導

智通港股解盤 | 擔憂地緣政治多數黃金股創歷史新高利好推動CXO全線走強

千億出海潮：中國創新藥企駛入全球深水區

國信證券：美國醫藥供應鏈新規出台關注CXO板塊投資機會

醫藥外包概念股逆市受壓康龍化成(03759)跌4.14% 機構指美生物安全法案對華CXO企業經營影響有限

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/CXO/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"CXO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CXO\",,,,,undefined,":{"symbol":"CXO","market":"US","secType":"STK","nameCN":"康休","latestPrice":65.6,"timestamp":1610744400000,"preClose":65.6,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":192489259,"shares":194506801,"eps":-52.266872,"marketStatus":"退市","change":0,"latestTime":"03-23 06:13:42 EDT","open":65.6,"high":65.6,"low":65.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-52.266872,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774272600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1186113600000,"exchange":"NYSE","adjPreClose":65.6,"dividendRate":0.011052,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CXO\",,,,,undefined,":{"symbol":"CXO","floatShares":192489259,"roa":"-30.69%","roe":"-77.91%","lyrEps":-3.548023,"shares":194506801,"dividePrice":0.725,"high":65.6,"amplitude":0,"preClose":65.6,"low":65.6,"week52Low":33.13,"pbRate":"1.64","week52High":90.52,"institutionHeld":0,"latestPrice":65.6,"eps":-52.266872,"divideRate":0.011052,"volume":0,"delay":0,"ttmEps":-52.266872,"open":65.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CXO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-01-19","symbol":"CXO","reason":null,"defaultRemindTime":1611066600000,"announcedDate":"2021-01-14","type":"delisting","dateTimestamp":1611032400000},{"market":"US","date":"2020-11-05","symbol":"CXO","amount":0.2,"defaultRemindTime":1604586600000,"name":"康休","payableDate":"2020-11-06","currency":"USD","type":"dividend","dateTimestamp":1604552400000},{"market":"US","date":"2020-10-27","symbol":"CXO","fiscalQuarterEnding":"2020/09","expectedEps":1.14,"name":null,"time":"盤後","type":"earning","dateTimestamp":1603771200000,"reportTimeType":"post","actualEps":1.43},{"market":"US","date":"2020-08-06","symbol":"CXO","amount":0.2,"defaultRemindTime":1596720600000,"name":"康休","payableDate":"2020-08-07","currency":"USD","type":"dividend","dateTimestamp":1596686400000},{"market":"US","date":"2020-07-29","symbol":"CXO","fiscalQuarterEnding":"2020/06","expectedEps":0.33,"name":null,"time":"盤後","type":"earning","dateTimestamp":1595995200000,"reportTimeType":"post","actualEps":1.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CXO\",market:\"US\",,,undefined,":[{"executeDate":"2019-02-28","recordDate":null,"paymentDate":null,"value":0.125,"currency":"USD"},{"executeDate":"2019-05-09","recordDate":"2019-05-10","paymentDate":null,"value":0.125,"currency":"USD"},{"executeDate":"2019-08-08","recordDate":"2019-08-09","paymentDate":null,"value":0.125,"currency":"USD"},{"executeDate":"2019-11-07","recordDate":"2019-11-08","paymentDate":null,"value":0.125,"currency":"USD"},{"executeDate":"2020-02-27","recordDate":"2020-02-28","paymentDate":null,"value":0.2,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CXO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CXO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CXO","date":"2021-01-15","current":-1.255097,"percent":0.244996,"low":-22.831021,"twenty":-14.937462,"median":17.448879,"eighty":43.624979,"high":142.858816,"avg":25.025998,"sd":38.430736,"marketCap":13577273687},"quantilePoints":[],"updateTime":1774260822160},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CXO\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621095723","title":"【券商聚焦】交銀國際：CXO行情持續回暖 料板塊估值倍數合理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621095723?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 10:25","pubTimestamp":1774232735,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，多重利好因素共振下，2025年以来CXO行情持续回暖。该机构建议重点关注标的细分赛道成长力、核心能力布局、盈利和订单增长能见度、地缘风险敞口及估值上升空间。基于此，该机构首推药明合联，首次覆盖并重点推荐凯莱英和康龙化成。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01789","LU2399975544.HKD","02367","LU0540923850.HKD","LU1303224171.USD","LU2476274720.SGD","01530","LU0634319403.HKD","LU1115378108.SGD","BK1197","06160","LU0348827113.USD","IE00BPRC5H50.USD","LU1719994722.HKD","IE00B543WZ88.USD","BK1161","LU0348766576.USD","LU0348767384.USD","LU2476274308.USD","LU2488822045.USD","BK1585","BK1588","09926","BK1593","LU1794554557.SGD","BK1583","BK1141","02196","01099","BK1574","LU2778985437.USD","03933","09688","BK1500","BK1191","LU1770034418.SGD","LU0348735423.USD","06821","BK1617","03329","LU2328871848.SGD","LU0417516571.SGD","02228","BK1207","LU0307460666.USD","LU0348784397.USD","LU0417516738.SGD","02268","LU0417516902.SGD","CXO"],"gpt_icon":0},{"id":"2620689789","title":"海納醫藥三度衝擊IPO：現金流吃緊、業績持續下滑，仿製藥CXO的故事不好講了","url":"https://stock-news.laohu8.com/highlight/detail?id=2620689789","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620689789?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 16:48","pubTimestamp":1773996480,"startTime":"0","endTime":"0","summary":"国内CXO行业景气度乍暖还寒之际，又一家“卖水人”顶着寒风冲刺港股IPO。南京海纳医药科技股份有限公司近日递表港交所，这已是该公司三年内第三次向资本市场发起冲击。此前，海纳医药经历过创业板IPO折戟，也曾试图“卖身”成都先导实现曲线上市未果，如今在现金流日益紧绷、业绩持续下滑的背景下，火速转道港股。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-03-20/doc-inhrrrew0753832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159399","CXO","BK1161","159938","BK1515","09939","BK1574"],"gpt_icon":0},{"id":"2620400710","title":"掘金港股醫藥板塊復甦！恒生生物科技 ETF華泰柏瑞（513930）上市，助力一鍵佈局創新藥+CXO 雙賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2620400710","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620400710?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 09:55","pubTimestamp":1773798900,"startTime":"0","endTime":"0","summary":"港股生物医药领域又添投资利器。2026年3月18日，华泰柏瑞基金旗下的恒生生物科技ETF华泰柏瑞重磅上市，为投资者助力一键布局港股优质生物医药资产提供便捷工具。　　据悉，恒生生物科技ETF华泰柏瑞跟踪的恒生生物科技指数是港股市场中唯一配备股指期货的医药类指数，主要反映香港上市且符合港股通资格的生物科技企业整体表现，涵盖通过上市规则第18A章上市的公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/2026-03-18/doc-inhrknay3386620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","159718","BK1161","CXO","06978","159892","BK4550","BK1574","FDN","BK4585","HBImain","BK4588"],"gpt_icon":0},{"id":"2620429123","title":"衝高回落！CXO、互聯網醫療力挺，華寶基金港股通醫療ETF（159137）成功連陽！創新藥分化，520880放量收平","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429123","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429123?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 19:24","pubTimestamp":1773746640,"startTime":"0","endTime":"0","summary":"3月17日，港股市场冲高回落，医药板块未能幸免。　　港股医疗核心资产——港股通医疗ETF华宝早盘一度摸高3.38%，最终收涨0.44%成功连阳。CXO及互联网医疗权重股力挺指数，金斯瑞生物科技涨3.74%，药明系集体收红，京东健康、阿里健康均收涨，平安好医生涨2.77%。　　创新药与医疗走势无差，100%创新药研发标的——港股通创新药ETF早盘一度冲击3%，最终平盘报收，交投维持高度活跃，放量成交5.15亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-17/doc-inhrhxzp8122894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159137","520880","520510","159992","BK1574","CXO","06978","BK1161"],"gpt_icon":0},{"id":"2620041459","title":"國信證券：CXO與器械板塊機會顯現 關注創新藥產業鏈及低估值板塊","url":"https://stock-news.laohu8.com/highlight/detail?id=2620041459","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620041459?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 09:45","pubTimestamp":1773711919,"startTime":"0","endTime":"0","summary":"近期，国产创新药在学术会议上读出优秀的临床数据，建议关注二季度的ASCO等重磅学术会议。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260317/20260317093554_26324.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260317/20260317093554_26324.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0028","BK0276","159992","BK0183","002736","BK1161","06978","BK1574","BK0188","CXO"],"gpt_icon":0},{"id":"2618195880","title":"2025年醫藥生物新股業績透視：CXO產業景氣好轉，創新藥企「摘U」崎嶇，降本增效極致博弈","url":"https://stock-news.laohu8.com/highlight/detail?id=2618195880","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618195880?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 20:12","pubTimestamp":1773144721,"startTime":"0","endTime":"0","summary":"2025年，A股医药生物行业出现新的变局，IPO热度回升。Wind数据显示，2025年，A股医药生物（申万一级，下同）行业共计迎来10只新股，与2024年相比实现翻倍。不过，时代商业研究院注意到，截至2026年2月末，2025年上市的10家医药生物企业中，已发布业绩快报或业绩预告的企业共计有8家，业绩呈现“冰火两重天”的格局，这背后或是周期、政策与商业模式形成的共振。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667670036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CXO","BK1161","163118","000808.SH","BK1574","159992","06978"],"gpt_icon":0},{"id":"2618601607","title":"萬聯證券：投融資與出海雙輪驅動 CXO迎來景氣度修復與全球化新周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2618601607","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618601607?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 10:50","pubTimestamp":1773111055,"startTime":"0","endTime":"0","summary":"医疗健康领域投融资金额持续增加2025年，全球共完成医疗健康领域一级市场投融资1930 笔，累计融资632亿美元，融资金额同比回升8.6%；中国医疗健康产业一级市场共达成797笔投融资交易，累计融资97亿美元，融资金额同比回升32.9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["161027","CXO"],"gpt_icon":0},{"id":"2616242408","title":"績優股扛旗，藥明系CXO領銜，醫療ETF、港股通醫療華寶ETF雙雙回血！企穩信號出現？","url":"https://stock-news.laohu8.com/highlight/detail?id=2616242408","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616242408?lang=zh_tw&edition=fundamental","pubTime":"2026-03-01 19:42","pubTimestamp":1772365320,"startTime":"0","endTime":"0","summary":"2月27日，A股医疗板块全天飘红，全市场规模最大医疗ETF盘中上探1.14%，成功收复年线，成交3.84亿元。场内持续溢价交易，显示买盘态度积极，此前3日512170累获逾1.9亿元净申购。　　绩优股惠泰医疗领涨8.24%，该公司业绩快报显示，2025年营收、归母净利润及扣非归母净利润均实现同比20%以上增长。　　港股医疗板块连跌多日后终于迎来反弹，港股通医疗ETF华宝下探历史新低后回升，日线终结六连阴。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-01/doc-inhpnwmf5292913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","VXUS","BK4550","159828","BK4585","512170","159891","VT","FDN","CXO"],"gpt_icon":0},{"id":"2613227499","title":"國金證券：國內製藥供應鏈景氣度上行持續 建議把握CXO行業兩大核心主線","url":"https://stock-news.laohu8.com/highlight/detail?id=2613227499","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613227499?lang=zh_tw&edition=fundamental","pubTime":"2026-02-22 18:59","pubTimestamp":1771757953,"startTime":"0","endTime":"0","summary":"展望2026年，建议把握优先布局行业龙头及聚焦海外业务占比高的标的两大CXO行业核心主线。国内企业密集布局并通过BD合作落地出海，成为全球药企核心合作标的。制药供应链：景气度上行持续，新技术方向带动产业扩容2025年以来，AI制药技术热度攀升、全球创新药景气度延续，再叠加国内生物医药投融资触底回升，行业市场关注度持续走高，基本面复苏趋势愈发明确。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","01477","600109","BK1191","BK0188","BK0183","BK0012","CXO","BK1574","BK0201","BK0276"],"gpt_icon":0},{"id":"2608844855","title":"腦機接口、AI醫療、CXO全面開花！低位佈局港股通醫療ETF（159137）或正當時","url":"https://stock-news.laohu8.com/highlight/detail?id=2608844855","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608844855?lang=zh_tw&edition=fundamental","pubTime":"2026-02-03 13:52","pubTimestamp":1770097920,"startTime":"0","endTime":"0","summary":"MACD金叉信号形成，这些股涨势不错！\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：杨赐","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-02-03/doc-inhkpkrf0233731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520510","CXO","159891","159137"],"gpt_icon":0},{"id":"2608857502","title":"CXO行業深度報告：三重紅利共振，開啓新一輪景氣上升周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2608857502","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608857502?lang=zh_tw&edition=fundamental","pubTime":"2026-02-02 17:53","pubTimestamp":1770025981,"startTime":"0","endTime":"0","summary":"慧博投研近日发布研究报告，对CXO行业进行点评，其主要内容包括：CXO（医疗研发外包）作为创新药产业链的重要环节，涵盖了从药物发现到商业化生产的全流程服务。经历了2021年下半年至2024年8月的阶段性回调后，行业最差的时期已经过去。随着海外降息周期的开启、国内创新药BD出海的热潮以及新分子领域的产业升级，CXO行业正开启新一轮的高景气上行周期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638803785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CXO"],"gpt_icon":0},{"id":"2608306028","title":"國信證券：小核酸CXO行業景氣度持續攀升 邁入臨床兑現與商業化加速階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2608306028","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608306028?lang=zh_tw&edition=fundamental","pubTime":"2026-02-02 14:30","pubTimestamp":1770013847,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，小核酸CXO作为小核酸药物产业的核心支撑，受益于技术突破与商业化加速，行业景气度持续攀升。小核酸CXO行业同步进入发展快车道，形成“研发服务-中试放大-商业化生产”的CRDMO全链条服务体系。报告中称，小核酸药物正迎来全球范围内的蓬勃发展期，已从技术验证阶段迈入临床兑现与商业化加速阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","002736","BK0028","CXO","BK0183","BK0276"],"gpt_icon":0},{"id":"2608884658","title":"陳果：春季行情未完，結構如何變化？","url":"https://stock-news.laohu8.com/highlight/detail?id=2608884658","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608884658?lang=zh_tw&edition=fundamental","pubTime":"2026-02-01 22:32","pubTimestamp":1769956320,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　受地缘局势升温、美联储主席提名落地及中美财报密集披露期等因素影响，本周市场波动加剧。　　春季行情未完，结构如何变化？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/report/2026-02-01/doc-inhkitqy8520391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","PCB","BK4211"],"gpt_icon":0},{"id":"2606930347","title":"國聯民生證券：全球CXO行業強勢復甦 2026年有望延續高景氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2606930347","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606930347?lang=zh_tw&edition=fundamental","pubTime":"2026-01-28 15:58","pubTimestamp":1769587104,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国联民生证券发布研报称，全球生物科技及药企投融资活动及交易需求在2025年显著回暖，创新药新技术平台蓬勃发展，驱动CXO行业下游需求全面复苏，行业景气度有望将、在2026年延续。中国市场IND数量同比增长19%，BD交易金额同比高增，国内创新药市场活力充沛，为CXO行业提供持续动能。国内临床CRO明确拐点，泰格医药受益行业复苏中国CRO市场于2025年重回增长轨道。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1564","601456","BK1147","01456","161027","BK0276","CXO"],"gpt_icon":0},{"id":"2605449493","title":"近五成生物醫藥公司業績預喜 多家CXO企業表現亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2605449493","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605449493?lang=zh_tw&edition=fundamental","pubTime":"2026-01-23 08:24","pubTimestamp":1769127883,"startTime":"0","endTime":"0","summary":"南方财经1月23日电，据中证报，截至1月22日，按照申万一级行业划分，已有逾50家生物医药企业披露2025年业绩预告，27家预喜，预喜比例近五成。值得关注的是，多家CXO（医药外包服务，包括CDMO和CRO）公司业绩表现亮眼。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601233628152649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","161726","BK4588","CXO","399441","LABU"],"gpt_icon":0},{"id":"2603955152","title":"西南證券：CXO行業關注新分子的成長性與國內景氣度修復的傳導","url":"https://stock-news.laohu8.com/highlight/detail?id=2603955152","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603955152?lang=zh_tw&edition=fundamental","pubTime":"2026-01-16 10:37","pubTimestamp":1768531037,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，西南证券发布研报称，CXO板块持续关注：1）全球市场多肽、偶联药物、寡核酸等新分子对R、D、M外包持续注入的增长动能；2）地缘风险不确定性出清后的反转与板块情绪面改善；3）国内市场景气度修复、创新药研发需求的传导；4）AI赋能的药物研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0183","BK0028","CXO","BK0276","BK0188","600369"],"gpt_icon":0},{"id":"2603681308","title":"智通港股解盤 | 擔憂地緣政治多數黃金股創歷史新高 利好推動CXO全線走強","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681308","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681308?lang=zh_tw&edition=fundamental","pubTime":"2026-01-13 20:42","pubTimestamp":1768308157,"startTime":"0","endTime":"0","summary":"恒指不敢持续发力，因为还是有担忧情绪，当地时间12日，美国国务院在网站上发布信息，要求美国公民立即离开伊朗。智通1月金股——紫金黄金国际也涨超5%，同样创出了上市以来的新高。中方将坚定维护自身正当合法权益。这对中国创新药企是好消息。近日，研究服务业务首付款和总付款金额再创新高，去年合作项目的潜在里程碑付款总额高达40亿美元以上。紫金矿业巨龙铜矿项目二期全面达产后，将新增日处理20万吨矿石的产能。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0708995583.HKD","BK1198","BK1583","HK0000252152.HKD","HK0000500386.USD","LU2242644610.SGD","SGXZ62798434.SGD","BK1117","SGXZ86797644.SGD","BK1205","BK1546","HK0000252160.HKD","LU1046422090.SGD","159562","02315","LU2213484517.USD","01072","LU2045819591.USD","CXO","BK1522","LU2125910500.SGD","LU0593848301.USD","BK1161","BK1576","02359","02259","LU0052750758.USD","LU2543165471.USD","LU0320764599.SGD","BK1141"],"gpt_icon":1},{"id":"2601854186","title":"千億出海潮：中國創新藥企駛入全球深水區","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854186","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601854186?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 07:13","pubTimestamp":1767654792,"startTime":"0","endTime":"0","summary":"中国药企不仅成为全球医药研发体系中不可忽视的力量，也在重新定义自身在国际市场上的角色。从首付款到里程碑款的持续流入，标志着中国创新药的全球开发已实质性推进至临床中后期乃至商业化阶段。这意味着中国药企不再只是技术提供方，而是以平等伙伴身份参与全球价值创造与分配。中国药企在跨境谈判、知识产权布局、国际争议解决等方面经验仍显不足。锻造出海“航母舰队”中国创新药的集体出海，离不开产业集群的支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01167","01541","01801","BK4139","CXO","06160","BK4526","ONC","BMS","02509","BK4585","00013"],"gpt_icon":0},{"id":"2594286909","title":"國信證券：美國醫藥供應鏈新規出台 關注CXO板塊投資機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2594286909","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594286909?lang=zh_tw&edition=fundamental","pubTime":"2025-12-25 09:40","pubTimestamp":1766626821,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，美国国会近日通过2026财年国防授权法案，其中纳入修订版《生物安全法案》相关条款，中国创新药产业长期竞争力仍受看好。建议关注CXO板块，并留意创新药海外临床进展。国信证券主要观点如下：《生物安全法案》获参、众议院通过，关注CXO板块投资机会美国时间12月17日，美国参议院以77票赞成、20票反对的表决结果，通过2026财年国防授权法案。法案后续将提交白宫，待美国总统签署生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK0188","BK0183","BK0276","BK1161","CXO","BK0028","BK1574","159938","09939","002736"],"gpt_icon":0},{"id":"2593657109","title":"醫藥外包概念股逆市受壓 康龍化成(03759)跌4.14% 機構指美生物安全法案對華CXO企業經營影響有限","url":"https://stock-news.laohu8.com/highlight/detail?id=2593657109","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593657109?lang=zh_tw&edition=fundamental","pubTime":"2025-12-22 14:06","pubTimestamp":1766383579,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念股逆市受压，截至发稿，康龙化成 跌4.14%，药明生物跌3.75%，药明康德跌2.89%，昭衍新药跌2.67%，泰格医药跌2.07%，金斯瑞生物科技跌1.36%。招银国际表示，MSCI中国医疗指数2025年初至今累计上涨51.9%，跑赢MSCI中国指数24.3%。近期，医药板块有所回调。政策端方面，《生物安全法案》虽已签署生效，但鉴于其未波及Medicaid和Medicare的采购且对关联方定义明确，以及中国CXO美国行政机构收入占比较小，该机构预计该法案对中国CXO企业实质经营影响有限。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1972004","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708995583.HKD","LU0320764599.SGD","06127","159938","BK0216","LU3063872942.SGD","LU0417516902.SGD","LU1242518931.SGD","02359","LU0359202008.SGD","LU0326950275.SGD","LU2039709279.SGD","LU0516423091.SGD","HK0000320264.USD","09939","LU0327786744.USD","LU0516423174.USD","CXO","BK1576","01548","HK0000306685.HKD","LU1880383366.USD","HK0000320223.HKD","LU0572944931.SGD","LU0359201612.USD","03759","BK1161","LU2125910500.SGD","LU1046422090.SGD","LU0348825331.USD","LU0417516738.SGD","LU0456846285.SGD","LU0051755006.USD","BK1610","LU0348735423.USD","LU0516422440.USD","BK1574","SG9999002562.SGD","HK0000306701.USD","03347","BK1141","300759","BK1583","LU0823426308.USD","BK1589","LU0819121731.USD","02269","LU0140636845.USD","SG9999002463.SGD","LU1720050803.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}]}}